505 Coast Boulevard South
62 articles about CalciMedica
CalciMedica Announces Independent Safety Review Committee Recommendation to Continue Phase 2 Study of CM4620-IE in Patients with Severe COVID-19 Pneumonia on Low-Flow Oxygen Therapy
CalciMedica Inc., a clinical-stage biotechnology company targeting calcium release-activated calcium channels for the treatment of acute and severe inflammatory diseases, announced that the Independent Safety Review Committee recommended that its open-label Phase 2 study evaluating the safety, efficacy and pharmacokinetic profile of CM4620-IE in patients with severe COVID-19 pneumonia continue as planned.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 7, 2020.
5/4/2020There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
CalciMedica Expands Clinical Study to Assess CM4620-IE in Patients with Critical COVID-19 Pneumonia on High-Flow Oxygen Therapy
Phase 2 open-label study expands to additional sites across the U.S. and aims to enroll 120 patients
4/20/2020There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 16, 2020.
4/13/2020It was a very busy week for clinical trial news. Here’s a look.
FDA Grants CalciMedica Permission to Begin Dosing CM4620-IE in Patients with Severe COVID-19 Pneumonia under a Newly Opened IND
Regions Hospital in St. Paul, Minnesota has begun a Phase 2 clinical study of CM4620-IE in patients with severe COVID-19 pneumonia this week, and Henry Ford Hospital in Detroit is expected to begin a trial within the next week
Henry Ford Hospital Physician Presents Results from the Initial Patient Study of CalciMedica's CRAC Channel Inhibitor CM4620 in Acute Pancreatitis at ACEP Meeting
Joseph Miller, MD, MS, a physician at the Henry Ford Health System in Detroit, MI, and a key Principal Investigator on CalciMedica's initial acute pancreatitis clinical study of its calcium release-activated calcium channel inhibitor CM4620-IE, presented on the study at the annual meeting of the American College of Emergency Physicians being held in Denver, CO from October 27-30.
CalciMedica, Inc. to Present Study Population Profile from its Initial Patient Study of its CRAC Channel Inhibitor CM4620 in Acute Pancreatitis at International Conference
Physicians from several study sites involved in CalciMedica's initial acute pancreatitis clinical study of its CRAC channel inhibitor CM4620 and CalciMedica, Inc., presented a poster at the 39th International Symposium on Intensive Care and Emergency Medicine being held in Brussels on March 19-22.
CalciMedica announced that the first patients in a Phase 2a clinical study for acute pancreatitis have been dosed with its proprietary calcium release-activated calcium (CRAC) channel inhibitor CM4620.
CalciMedica announced that it named two independent members to its Board of Directors, Lakhmir Chawla, MD, currently Chief Medical Officer of La Jolla Pharmaceuticals Company (NASDAQ: LJPC), and Christopher Krueger, JD, MBA, a co-founder and Chief Business Officer of Escalier Biosciences.
CalciMedica Receives Fast-Track Designation For CM4620, A Novel CRAC Channel Inhibitor To Treat Acute Pancreatitis
CalciMedica And University of Liverpool Announce Publication On CRAC Channel Inhibitors For Acute Pancreatitis